Join us on Tuesday, October 3^rd for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists and other allied healthcare professionals involved in the treatment of melanoma.

Learning Objectives
Upon completion of this activity, participants should be able to

• Formulate a long-term clinical plan for the management of locally advanced or metastatic basal cell carcinoma (BCC), incorporating targeted and immunotherapeutic strategies.
• Use available clinical trial evidence to safely and effectively integrate immunotherapeutic approaches into the care of patients with locally advanced or metastatic cutaneous squamous cell carcinoma (cSCC).
• Evaluate available clinical research findings with targeted and immunotherapeutic agents as neoadjuvant or adjuvant therapy for patients with cSCC and BCC to determine the current and potential clinical utility of these approaches.
• Recall the rationale for and design of ongoing clinical trials evaluating novel agents and strategies for cSCC and BCC, and appropriately counsel patients about availability and participation.

CE Credit
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Faculty disclosures to be provided.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Khushalani — Advisory Committee: Bristol Myers Squibb, Castle Biosciences Incorporated, Genzyme Corporation, Instil Bio, Iovance Biotherapeutics, Merck, Nektar, Novartis, Regeneron Pharmaceuticals Inc, Replimune; Contracted Research: Bristol Myers Squibb, Celgene Corporation, GSK, HUYA Bioscience International, Merck, Modulation Therapeutics, Novartis, Regeneron Pharmaceuticals Inc, Replimune; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, Incyte Corporation; Stock Options/Ownership — Public Company: Amarin Corporation, Asensus Surgical, Bellicum Pharmaceuticals Inc; Study Steering Committee: Bristol Myers Squibb, Nektar, Regeneron Pharmaceuticals Inc, Replimune; Travel Remuneration: Regeneron Pharmaceuticals Inc. Dr Pavlick — Advisory Committee: Bristol Myers Squibb, Regeneron Pharmaceuticals Inc, Replimune; Consulting Agreements: Bristol Myers Squibb, Merck, Regeneron Pharmaceuticals Inc, Replimune; Contracted Research: Merck, Replimune.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

SURVEY PARTICIPANTS — Omid Hamid, MD — Advisory Committee and Consulting Agreements: Alkermes, Amgen Inc, Bactonix, BeiGene Ltd, BioAtla, Bristol Myers Squibb, Eisai Inc, Genentech, a member of the Roche Group, Georgiamune, GigaGen, GSK, Grit Bio, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Instil Bio, IO Biotech, Iovance Biotherapeutics, Janssen Biotech Inc, KSQ Therapeutics, Merck, Moderna, Novartis, Obsidian Therapeutics, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Tempus, Zelluna Immunotherapy AS; Contracted Research: Akeso Inc, Amgen Inc, Arcus Biosciences, BioAtla, Bristol Myers Squibb, Chinook Therapeutics, CytomX Therapeutics, Exelixis Inc, Genentech, a member of the Roche Group, GSK, Idera Pharmaceuticals Inc, Immunocore, Incyte Corporation, Iovance Biotherapeutics, Merck, Merck Serono, Moderna, NextCure, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, Repertoire Immune Medicines, Seagen Inc, Zelluna Immunotherapy AS; Speakers Bureau: Bristol Myers Squibb, Immunocore, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc; Nonrelevant Financial Relationship: Vial. Evan J Lipson, MD — Advisory Committee: Bristol Myers Squibb, Genentech, a member of the Roche Group, Merck; Consulting Agreements: CareDx, Eisai Inc, HUYA Bioscience International, Immunocore, Instil Bio, Merck KGaA, Natera Inc, Nektar, Novartis, OncoSec Medical, Pfizer Inc, Rain Oncology, Regeneron Pharmaceuticals Inc, Replimune, Sanofi; Contracted Research: Bristol Myers Squibb, Merck, Regeneron Pharmaceuticals Inc, Sanofi. Sunil Arani Reddy, MD — No relevant conflicts of interest to disclose. Jeffrey S Weber, MD, PhD — Advisory Board: Bristol Myers Squibb; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Biond Biologics, Celldex Therapeutics, EMD Serono Inc, Evaxion Biotech A/S, Genentech, a member of the Roche Group, GSK, ImCheck Therapeutics, Incyte Corporation, Merck, Moderna, Nektar, Novartis, Pfizer Inc, Regeneron Pharmaceuticals Inc, SELLAS Life Sciences; Equity (Options): Biond Biologics, OncoC4; Patents: Moffitt Cancer Center filed a patent on an ipilimumab biomarker and on TIL preparation that I am named on, and Biodesix filed a PD-1 patent that I was named on; Research Support to Institution: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, GSK, Merck, Moderna, Novartis, Pfizer Inc; Scientific Advisory Board: Biond Biologics, CytomX Therapeutics, ImCheck Therapeutics, Incyte Corporation, Instil Bio, NexImmune, OncoC4, SELLAS Life Sciences.